Noticias y vídeos - NANO-X IMAGING LTD

ADOPT Study Findings Highlight Nanox.AI’s Role in Enhancing Fracture Detection and Healthcare Cost Savings PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd will present new data from the A I-enabled D etection of O steo P orosis for T reatment (ADOPT) study at four major upcoming medical...

PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024, before market open on Monday, March 31, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a...

In a clinical study, it was found that the Nanox.ARC digital tomosynthesis enhanced musculoskeletal imaging, can improve the sensitivity and specificity of conventional radiography. In addition, can improve cast and metal imaging, eliminate the need for CT in some cases while at the same time reducing the patient radiation exposure and radiologist reading time. The Nanox.ARC outperformed standard x-ray in detecting lung nodules under simulated obesity conditions in phantoms PETACH TIKVA, Israel,...

CE Mark is the first major regulatory milestone for Nanox.ARC Imaging System in the European market; follows recent general use FDA clearance in the U.S. New clinical data supporting use of Nanox.ARC to be presented at European Congress of Radiology (ECR) 2025. Nanox.ARC is an FDA, CE Marked, digital multi-source 3D tomosynthesis imaging system, providing advanced radiographic visualization. Nanox.ARC unlocks significant value for medical practices, providers, and their patients. PETACH TIKVA,...

Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication for the musculoskeletal system Nanox.ARC uses high voltage powered digital X-ray tubes for 3D tomosynthesis imaging that could help expand availability of medical imaging Nanox.ARC now deployed at healthcare facilities across seven states in the U.S. PETACH TIKVA, Israel, Dec. 05, 2024 (GLOBE...

Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, today announced results for the...

PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2024, before market open on Thursday, November 21, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business...

Nanox AI’s Solutions selected for Special Mention on annual list recognizing the most impactful new products and ideas PETACH TIKVA, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, NanoxAI Ltd. (Nanox AI), was selected for a Special Mention in the TIME’s Best Inventions of 2024 list. TIME’s annual Best...

PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will participate in an investor conference in the month of September 2024: Cantor Fitzgerald Global Healthcare Conference About Cantor Fitzgerald Global Healthcare Conference Nanox’s Chief Executive Officer and Acting Chairman, Erez Meltzer, and Chief Financial Officer, Ran Daniel,...

HealthCCSng V2.0 i ntroduces additional ‘ zero calcium ’ categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC d etection c ategory output Marks second FDA 510(k) clearance of HealthCCSng product PETACH TIKVA, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics...

Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications to include general use, including chest Nanox.AI Receives FDA 510K Clearance for HealthCCSng V 2.0, upgraded version of its AI Cardiac Solution Management to host conference call and webcast Tuesday, August 20, 2024 at 8:30 AM ET PETAH TIKVA, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an...

PETACH TIKVA, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2024, before market open on Tuesday, August 20, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update...

In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards’ Winner In a study conducted by Jefferson Einstein Hospital, Nanox.AI Cardiac Solution Flags CAD High-Risk Patients, Drives Significant Revenue Additional data presented by Corewell Health, Massachusetts General Hospital and Rabin Medical Center PETACH TIKVA, Israel, July...

PETACH TIKVA, Israel, June 25, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT), being held July 18-21 in Washington, D.C. The studies are being presented by esteemed...

Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service New AI capabilities a vailable to patients who submit chest and abdominal CT scans for second opinions Offering the power of Artificial Intelligence to their second opinion CT report to p romote early detection of chronic conditions PETACH TIKVA, Israel, June 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company,...

Accelerates Deployment of Nanox.ARC in United States Signed two commercial agreements for Nanox.AI Management to host conference call and webcast Tuesday, May 28, 2024 at 8:30 AM ET PETAH TIKVA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2024 and provided a business update. First Quarter 2024 Highlights and Recent...

PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2024, before market open on Tuesday, May 28, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m....

Company earns Gold Seal of Approval® for Ambulatory Health Care Accreditation PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its wholly-owned subsidiary, USARAD Holdings, Inc., a leading provider of teleradiology services, has earned The Joint Commission’s Gold Seal of Approval ® for Ambulatory Health Care Accreditation for the sixth time by...

PETACH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announces that Company management will participate in three investor conferences in the month of May 2024: EF Hutton 2024 Annual Global Conference AGP 2024 Healthcare Conference Benchmark 2024 Healthcare House Call Virtual Conference About EF Hutton 2024 Annual Global Conference Nanox’s Chief Executive Officer, Erez...

PETACH TIKVA, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (“SEC”) on April 22, 2024. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the...